ALPACAR-360 Success And AstraZeneca Collaboration Will Advance siRNA Pipeline

Key Takeaways

• The company's strategic partnerships and collaborations could reduce financial risk and enhance revenue growth through shared commercialization and milestone payments.
  
• Successful study results and orphan drug designation might lead to dominance in niche markets, improving future earnings and net margins.
  
• Financial challenges from net operating losses, rising R&D costs, and partnership uncertainties could impact future earnings, revenue projections, and net margins.

Catalysts

A biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.

• The positive results from the ALPACAR-360 Phase II study for zerlasiran and its differentiated Phase III program design can provide a competitive edge in treating high Lp(a) levels, potentially leading to strong future revenue growth upon successful completion and commercialization.
  
• Advancing the divesiran program with strong Phase I results and the orphan drug designation for PV could lead to dominance in a niche market, thereby improving the company's future earnings and net margins due to premium pricing in rare disease markets.
  
• Securing a partner for the Phase III zerlasiran study is a strategic move that extends cash runway and reduces financial risk, potentially enhancing net margins by lowering upfront R&D costs and sharing future commercialization expenses.
  
• The collaboration with AstraZeneca and the potential to earn additional milestones from new siRNA targets could lead to increased milestone payments and licensing revenues, positively impacting overall revenue growth.
  
• Prioritizing investments in rare condition targets within the siRNA pipeline where Silence has competitive therapeutic potential may lead to high-value partnerships and an expansion in revenue streams, supporting long-term financial growth and stability.

Silence Therapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Silence Therapeutics's revenue will grow by 226.0% annually over the next 3 years.
• Analysts are not forecasting that Silence Therapeutics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Silence Therapeutics's profit margin will increase from -8943.9% to the average GB Biotechs industry of 19.0% in 3 years.
• If Silence Therapeutics's profit margin were to converge on the industry average, you could expect earnings to reach $5.5 million (and earnings per share of $0.12) by about June 2029, up from -$75.0 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 332.4x on those 2029 earnings, up from -4.2x today. This future PE is greater than the current PE for the GB Biotechs industry at 16.5x.
• Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.55%, as per the Simply Wall St company report.

Risks

• The company's financial performance shows a net operating loss for the full year of 2024, which may indicate longer-term financial challenges that could impact future earnings.
  
• The ongoing partnership discussions and dependence on securing a partner to initiate the zerlasiran Phase III outcomes study reflect significant financial uncertainty, which could affect the company's revenue projections.
  
• The decision by Hansoh Pharma not to pursue further development under the collaboration suggests potential challenges in forming successful partnerships, which could impact future revenue and milestones.
  
• R&D costs have risen due to advancing proprietary programs, increasing the net loss which could impact net margins and create financial strain if not balanced by increased revenues or successful partnerships.
  
• The transition to U.S. domestic issuer status entails additional legal and accounting expenses, affecting administrative costs and potentially squeezing net margins further.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $31.2 for Silence Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $75.0, and the most bearish reporting a price target of just $4.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $29.1 million, earnings will come to $5.5 million, and it would be trading on a PE ratio of 332.4x, assuming you use a discount rate of 7.5%.
• Given the current share price of $6.69, the analyst price target of $31.2 is 78.6% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.